Presbyopia is the gradual loss of the eyes’ ability to focus on nearby objects that impact people over 45 years.
Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity.
In the vehicle-controlled CLARITY 2 trial, the Day 1 results showed:
Near vision improvement was reproducible and consistent across CLARITY 1 and 2 throughout the four-week study periods.
LNZ100 was well-tolerated, with no serious treatment-related adverse events observed in the over 30,000 treatment days across all three CLARITY trials.
LNZ101 showed similar results, including achieving primary and secondary endpoints in CLARITY 1 and 2, but did not show superiority to LNZ100. Hence, LENZ selected LNZ100 as its lead product candidate, for which it plans to submit a New Drug Application in mid-2024.
Near vision improvement was reproducible and consistent across CLARITY 1 and 2 throughout the four-week study periods.
LNZ100 was well-tolerated, with no treatment-related serious adverse events observed.
Price Action: LENZ shares are up 4.33% at $21.92 on the last check Wednesday.
Photo by Amanda Dalbjörn on Unsplash
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
